Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

被引：0
|
作者：
N B Leighl
J Bennouna
J Yi
N Moore
J Hambleton
H Hurwitz
机构：
[1] Princess Margaret Hospital,Division of Medical Oncology
[2] Centre René Gauducheau,Division of Medical Oncology
[3] Genentech,Division of Medical Oncology
[4] Inc.,undefined
[5] Hoffman-La Roche,undefined
[6] Inc.,undefined
[7] Duke University School of Medicine,undefined
来源：
British Journal of Cancer | 2011年 / 104卷
关键词：
bevacizumab; non-small cell lung cancer; colorectal cancer; anticoagulation; haemorrhage; safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：413 / 418
页数：5
相关论文
共 50 条
  • [31] Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC)
    Sandler, A. B.
    Hirsh, V.
    Reck, M.
    Archer, V.
    Samant, M. K.
    Wang, L.
    Strickland, D. K.
    Dimery, I.
    Johnson, D. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab.
    Takahashi, Naoki
    Iwasa, Satoru
    Tachikawa, Masanori
    Fukahori, Masaru
    Sudo, Kazuki
    Sasaki, Yusuke
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko
    Takashima, Atsuo
    Hamaguchi, Tetsuya
    Boku, Narikazu
    Shimada, Yasuhiro
    Yamagiwa, Koki
    Ebata, Yuka
    Uchida, Yasuo
    Honda, Kazufumi
    Terasaki, Tetsuya
    Yamada, Yasuhide
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [33] Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab
    Wills, Beatriz
    Cardona, Andres F.
    Rojas, Leonardo
    Ruiz-Patino, Alejandro
    Arrieta, Oscar
    Reguart, Noemi
    Carranza, Hernan
    Vargas, Carlos
    Otero, Jorge
    Corrales, Luis
    Martin, Claudio
    Cuello, Mauricio
    Eduardo Pino, Luis
    Rolfo, Christian
    Rosell, Rafael
    Lucia Zatarain-Barron, Zyanya
    ANTICANCER RESEARCH, 2017, 37 (11) : 6429 - 6436
  • [34] Effectiveness and safety of 6-months' treatment with different full-dose enoxaparin regimens in patients with cancer-associated venous thromboembolism: a subgroup analysis of the RIETECAT cohort study
    Monreal, M.
    Bertoletti, L.
    Lopez-Nunez, J. J.
    Tiberio, G.
    Soler, S.
    Gomez-Cuervo, C.
    Fidalgo, A.
    Mellado, M.
    Lopez-Miguel, P.
    Diaz-Peromingo, J. A.
    THROMBOSIS RESEARCH, 2022, 213 : S8 - S9
  • [35] A Retrospective Dosimetric Study in Breast Cancer Patients Who Received Conformal Radiation Therapy for Achievability of Recommended Dose Constraints of RTOG, DBCG, EORTC for Lung and Heart
    K, R. B.
    Siddique, S.
    Sebastian, P.
    Backianathan, S.
    B, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E182 - E182
  • [36] Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study
    Vainshtein, Jeffrey M.
    Schipper, Matthew
    Zalupski, Mark M.
    Lawrence, Theodore S.
    Abrams, Ross
    Francis, Isaac R.
    Khan, Gazala
    Leslie, William
    Ben-Josef, Edgar
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (01): : 96 - 101
  • [37] Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen. results from the brite observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Feng, S.
    Purdie, D.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Flynn, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [38] Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study
    Thaker, Premal H.
    Boyle, Tirza
    Perhanidis, Jessica
    Burns, Sara
    Lim, Jonathan
    Hartman, John
    Kalilani, Linda
    Schilder, Jeanne
    Hurteau, Jean
    Golembesky, Amanda
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S199 - S200
  • [39] Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study
    Thaker, Premal H.
    Boyle, Tirza Areli Calderon
    Burns, Sara
    Lim, Jonathan
    Hartman, John
    Kalilani, Linda, V
    Schilder, Jeanne M.
    Hurteau, Jean A.
    Golembesky, Amanda K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
  • [40] A prospective observational study with dose volume parameters predicting rectosigmoidoscopic findings and late rectosigmoid bleeding in patients with uterine cervical cancer treated by definitive radiotherapy
    Tae Hyun Kim
    Joo-Young Kim
    Dae Kyung Sohn
    Yeon-Joo Kim
    Yoon-Seok Lee
    Sung Ho Moon
    Sang Soo Kim
    Dae Yong Kim
    Radiation Oncology, 8
12345